Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.

In 2014, the FDA approved two drugs for idiopathic pulmonary fibrosis that posed a regulatory challenge: the primary efficacy variable studied was the change in forced vital capacity, which hadn't been established as a surrogate for clinically meaningful benefit.